Maintenance Notice (4:30 AM - 11:00 AM December 21, 2024): This website is scheduled to be unavailable due to maintenance. We appreciate your patience and understanding.
Published TCIMAIL newest issue No.197
Maximum quantity allowed is 999
Please select the quantity
CAS RN: 41575-94-4 | Product Number: C2043
Carboplatin
×
![]()
×
Purity: >98.0%(HPLC)
Synonyms:
- cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II)
Product Documents:
| Size | Unit Price | Belgium | Japan* | Quantity |
|---|---|---|---|---|
| 100MG |
50,00 €
|
2 | ≥60 |
|
| 1G |
312,00 €
|
2 | ≥60 |
|
*Stock available in Belgium will be delivered in 1 to 3 days
*Stock available in Japan will be delivered in 1 to 2 weeks (excludes regulated items and dry ice shipments).
| Product Number | C2043 |
| Purity / Analysis Method | >98.0%(HPLC) |
| Molecular Formula / Molecular Weight | C__6H__1__2N__2O__4Pt = 371.26 |
| Physical State (20 deg.C) | Solid |
| Storage Temperature | Room Temperature (Recommended in a cool and dark place, <15°C) |
| Packaging and Container | 100MG-Glass Bottle with Plastic Insert (View image), 1G-Glass Bottle with Plastic Insert (View image) |
| CAS RN | 41575-94-4 |
| Reaxys Registry Number | 13598388 |
| PubChem Substance ID | 87558792 |
| SDBS (AIST Spectral DB) | 51440 |
| Merck Index (14) | 1822 |
Specifications
| Appearance | White to Light yellow powder to crystal |
| Purity(HPLC) | min. 98.0 area% |
Properties (reference)
| Solubility in water | Soluble |
GHS
| Pictogram |
|
| Signal Word | Warning |
| Hazard Statements | H302 + H312 + H332 : Harmful if swallowed, in contact with skin or if inhaled. H315 : Causes skin irritation. H319 : Causes serious eye irritation. |
| Precautionary Statements | P261 : Avoid breathing dust. P264 : Wash skin thoroughly after handling. P280 : Wear protective gloves/ protective clothing/ eye protection/ face protection/ hearing protection. P337 + P313 : If eye irritation persists: Get medical advice/ attention. P302 + P352 + P312 : IF ON SKIN: Wash with plenty of water. Call a POISON CENTER/doctor if you feel unwell. P304 + P340 + P312 : IF INHALED: Remove person to fresh air and keep comfortable for breathing. Call a POISON CENTER/doctor if you feel unwell. |
Related Laws:
| EC Number | 255-446-0 |
| RTECS# | TP2300000 |
Transport Information:
| HS Number | 2843909000 |
Application
Platinum Coordination Complexes as Antitumor Agents
The development of platinum coordination complexes as antitumor agents began in the 1960s, and the highest antitumor activity was exhibited by cisplatin [D3371], approved by FDA in 1978. Improved versions carboplatin and oxaliplatin [O0372] were developed to avoid the serious side effects and the problem with resistance associated with the use of cisplatin.1-5)
The platinum complexes diffuse to the tumor cell, where they undergo hydrolysis displacement of their one chloride or carboxylate group leading to a platinum cation. The resulting cation coordinates to the guanine N7-position of DNA give a coordination cation. Then, intrastrand cross-linking occurs to anther guanine via further hydrolysis displacement of the remaining chloride or carboxylate. The forming [Pt(NH2R)2]2+ ― DNA complex distort the DNA helix (Fig. 1 and 2)6). Thus, DNA duplication is hindered, which ultimately triggers tumor cell apoptosis.3)
The platinum complexes diffuse to the tumor cell, where they undergo hydrolysis displacement of their one chloride or carboxylate group leading to a platinum cation. The resulting cation coordinates to the guanine N7-position of DNA give a coordination cation. Then, intrastrand cross-linking occurs to anther guanine via further hydrolysis displacement of the remaining chloride or carboxylate. The forming [Pt(NH2R)2]2+ ― DNA complex distort the DNA helix (Fig. 1 and 2)6). Thus, DNA duplication is hindered, which ultimately triggers tumor cell apoptosis.3)
References
- 1)G. Mathe, Y. Kidani, M. Segiguchi, M. Eriguchi, G. Fredj, G. Peytavin, J. L. Misset, S. Brienza, F. de Vassals, E. Chenu, C. Bourut, Biomed. Pharmacother. 1989, 43, 237.
- 2)L. R. Kelland, S. Y. Sharp, C. F. O’Neill, F. I. Raynaud, P. J. Beale, I. R. Judson, J. Inorg. Biochem. 1999, 77, 111.
- 3)D. Wang, S. J. Lippard, Nat. Rev. Drug Discov. 2005, 4, 307.
- 4)S. Trzaska, Chem. Eng. News 2005, 83, 3.
- 5)L. P. Martin, T. C. Hamilton, R. J. Schilder, Clin. Cancer Res. 2008, 14, 1291.
- 6)A. Gelasco, S. J. Lippard, Biochemistry, 1998, 37, 9230.
Application
Reviews on the Biochemical Mechanisms of Action of Carboplatin
References
- Cellular processing of platinum anticancer drugs
- Molecular mechanisms of resistance and toxicity associated with platinating agents
- Mechanisms of resistance to cisplatin and carboplatin
PubMed Literature
Articles/Brochures
TCIMAIL
Product Documents (Note: Some products will not have analytical charts available.)
Safety Data Sheet (SDS)
Please select Language.
The requested SDS is not available.
Please Contact Us for more information.
Specifications
C of A & Other Certificates
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
Sample C of A
This is a sample C of A and may not represent a recently manufactured lot of the product.
A sample C of A for this product is not available at this time.
Analytical Charts
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
The requested analytical chart is not available. Sorry for the inconvenience.